196 related articles for article (PubMed ID: 26684862)
1. Different Hormonal Expression Patterns Between Primary Pancreatic Neuroendocrine Tumors and Metastatic Sites.
Kimura H; Ohtsuka T; Fujimoto T; Date K; Matsunaga T; Cases AI; Abe A; Mizuuchi Y; Miyasaka Y; Ito T; Oda Y; Nakamura M; Tanaka M
Pancreas; 2016 Aug; 45(7):947-52. PubMed ID: 26684862
[TBL] [Abstract][Full Text] [Related]
2. Expression of glucagon-like Peptide 1 receptor and its effects on biologic behavior in pancreatic neuroendocrine tumors.
Cases AI; Ohtsuka T; Fujino M; Ideno N; Kozono S; Zhao M; Ohuchida K; Aishima S; Nomura M; Oda Y; Mizumoto K; Tanaka M
Pancreas; 2014 Jan; 43(1):1-6. PubMed ID: 24326362
[TBL] [Abstract][Full Text] [Related]
3. Hormonally defined pancreatic and duodenal neuroendocrine tumors differ in their transcription factor signatures: expression of ISL1, PDX1, NGN3, and CDX2.
Hermann G; Konukiewitz B; Schmitt A; Perren A; Klöppel G
Virchows Arch; 2011 Aug; 459(2):147-54. PubMed ID: 21739268
[TBL] [Abstract][Full Text] [Related]
4. Analysis of lymph node metastasis in pancreatic neuroendocrine tumors (PNETs) based on the tumor size and hormonal production.
Tsutsumi K; Ohtsuka T; Mori Y; Fujino M; Yasui T; Aishima S; Takahata S; Nakamura M; Ito T; Tanaka M
J Gastroenterol; 2012 Jun; 47(6):678-85. PubMed ID: 22350698
[TBL] [Abstract][Full Text] [Related]
5. EPB41L5 is Associated With the Metastatic Potential of Low-grade Pancreatic Neuroendocrine Tumors.
Saller J; Seydafkan S; Shahid M; Gadara M; Cives M; Eschrich SA; Boulware D; Strosberg JR; Aejaz N; Coppola D
Cancer Genomics Proteomics; 2019; 16(5):309-318. PubMed ID: 31467225
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathologic and prognostic significance of multiple hormone expression in pancreatic neuroendocrine tumors.
Kim JY; Kim MS; Kim KS; Song KB; Lee SH; Hwang DW; Kim KP; Kim HJ; Yu E; Kim SC; Jang HJ; Hong SM
Am J Surg Pathol; 2015 May; 39(5):592-601. PubMed ID: 25602797
[TBL] [Abstract][Full Text] [Related]
7. Retrospective study of 77 pancreatic endocrine tumors using the immunoperoxidase method.
Mukai K; Grotting JC; Greider MH; Rosai J
Am J Surg Pathol; 1982 Jul; 6(5):387-99. PubMed ID: 6127037
[TBL] [Abstract][Full Text] [Related]
8. Metachronous hormonal syndromes in patients with pancreatic neuroendocrine tumors: a case-series study.
de Mestier L; Hentic O; Cros J; Walter T; Roquin G; Brixi H; Lombard-Bohas C; Hammel P; Diebold MD; Couvelard A; Ruszniewski P; Cadiot G
Ann Intern Med; 2015 May; 162(10):682-9. PubMed ID: 25984844
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic neuroendocrine tumors in twelve baboons (Papio spp.).
Owston MA; LaRue MK; Dick EJ; Ambrus A; Porter BF
J Med Primatol; 2016 Apr; 45(2):85-91. PubMed ID: 26899153
[TBL] [Abstract][Full Text] [Related]
10. Clinically Significant Differences in Ki-67 Proliferation Index Between Primary and Metastases in Resected Pancreatic Neuroendocrine Tumors.
Richards-Taylor S; Tilley C; Jaynes E; Hu H; Armstrong T; Pearce NW; Plant R; Cave J
Pancreas; 2017; 46(10):1354-1358. PubMed ID: 28984786
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic neuroendocrine tumors.
Batcher E; Madaj P; Gianoukakis AG
Endocr Res; 2011; 36(1):35-43. PubMed ID: 21226566
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of membrane proteins in primary and metastatic gastrointestinal neuroendocrine tumors.
Carr JC; Sherman SK; Wang D; Dahdaleh FS; Bellizzi AM; O'Dorisio MS; O'Dorisio TM; Howe JR
Ann Surg Oncol; 2013 Dec; 20 Suppl 3(0 3):S739-S746. PubMed ID: 24114056
[TBL] [Abstract][Full Text] [Related]
13. Incidental diagnosis as prognostic factor in different tumor stages of nonfunctioning pancreatic endocrine tumors.
Crippa S; Partelli S; Zamboni G; Scarpa A; Tamburrino D; Bassi C; Pederzoli P; Falconi M
Surgery; 2014 Jan; 155(1):145-53. PubMed ID: 24646958
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological characteristics of non-functioning cystic pancreatic neuroendocrine tumors.
Nakashima Y; Ohtsuka T; Nakamura S; Mori Y; Nakata K; Miyasaka Y; Ishigami K; Matsuda R; Oda Y; Nakamura M
Pancreatology; 2019 Jan; 19(1):50-56. PubMed ID: 30497875
[TBL] [Abstract][Full Text] [Related]
15. Surgical Management of Pancreatic Neuroendocrine Tumors.
Clancy TE
Hematol Oncol Clin North Am; 2016 Feb; 30(1):103-18. PubMed ID: 26614371
[TBL] [Abstract][Full Text] [Related]
16. The Clinical Features and Molecular Mechanisms of ACTH-secreting Pancreatic Neuroendocrine Tumors.
Zhang C; Jin J; Xie J; Ye L; Su T; Jiang L; Zhou W; Jiang Y; Wu L; Wang T; Zhong X; Ning G; Shen B; Wang W
J Clin Endocrinol Metab; 2020 Nov; 105(11):. PubMed ID: 32785672
[TBL] [Abstract][Full Text] [Related]
17. Clinical features of pancreatic neuroendocrine tumors.
Grozinsky-Glasberg S; Mazeh H; Gross DJ
J Hepatobiliary Pancreat Sci; 2015 Aug; 22(8):578-85. PubMed ID: 25689919
[TBL] [Abstract][Full Text] [Related]
18. A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
Saif MW; Kaley K; Brennan M; Garcon MC; Rodriguez G; Rodriguez T
JOP; 2013 Sep; 14(5):498-501. PubMed ID: 24018594
[TBL] [Abstract][Full Text] [Related]
19. Synchronous Insulinoma and Glucagonoma: A Review of the Literature.
Damaskos C; Dimitroulis D; Garmpi A; Antoniou EA; Kouraklis G; Psilopatis I; Mavri M; Diamantis E; Marinos G; Kyriakos G; Farmaki P; Patsouras A; Kontzoglou K; Garmpis N
In Vivo; 2023; 37(6):2402-2408. PubMed ID: 37905620
[TBL] [Abstract][Full Text] [Related]
20. Multiple and Secondary Hormone Secretion in Patients With Metastatic Pancreatic Neuroendocrine Tumours.
Crona J; Norlén O; Antonodimitrakis P; Welin S; Stålberg P; Eriksson B
J Clin Endocrinol Metab; 2016 Feb; 101(2):445-52. PubMed ID: 26672633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
